Goldman Sachs’s AbbVie ABBV Stock Holding History

Goldman Sachs’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.29B	Buy	15,145,279 +2,149,654	+17%	+$477M	0.38%	28
2025 Q4	$2.97B	Sell	12,995,625 -399,594	-3%	-$91M	0.36%	33
2025 Q3	$3.1B	Buy	13,395,219 +1,226,757	+10%	+$250M	0.38%	35
2025 Q2	$2.26B	Sell	12,168,462 -1,981,546	-14%	-$368M	0.31%	45
2025 Q1	$2.96B	Buy	14,150,008 +2,854,787	+25%	+$555M	0.48%	27
2024 Q4	$2.01B	Buy	11,295,221 +612,902	+6%	+$113M	0.32%	47
2024 Q3	$2.11B	Sell	10,682,319 -928,570	-8%	-$173M	0.34%	47
2024 Q2	$1.99B	Buy	11,610,889 +2,725,088	+31%	+$451M	0.34%	44
2024 Q1	$1.62B	Sell	8,885,801 -1,734,645	-16%	-$299M	0.29%	55
2023 Q4	$1.65B	Sell	10,620,446 -113,628	-1%	-$16.6M	0.3%	53
2023 Q3	$1.6B	Buy	10,734,074 +1,413,745	+15%	+$208M	0.34%	45
2023 Q2	$1.26B	Sell	9,320,329 -799,125	-8%	-$117M	0.27%	61
2023 Q1	$1.61B	Buy	10,119,454 +1,282,296	+15%	+$196M	0.37%	36
2022 Q4	$1.43B	Sell	8,837,158 -574,540	-6%	-$88.1M	0.35%	35
2022 Q3	$1.26B	Buy	9,411,698 +796,517	+9%	+$114M	0.32%	44
2022 Q2	$1.32B	Sell	8,615,181 -610,746	-7%	-$93.3M	0.33%	40
2022 Q1	$1.5B	Sell	9,225,927 -428,133	-4%	-$62.2M	0.31%	40
2021 Q4	$1.31B	Sell	9,654,060 -223,702	-2%	-$26.4M	0.26%	51
2021 Q3	$1.07B	Buy	9,877,762 +3,026,131	+44%	+$346M	0.23%	58
2021 Q2	$772M	Buy	6,851,631 +285,052	+4%	+$32.1M	0.17%	94
2021 Q1	$711M	Sell	6,566,579 -1,687,475	-20%	-$180M	0.18%	89
2020 Q4	$884M	Sell	8,254,054 -1,845,258	-18%	-$177M	0.23%	63
2020 Q3	$885M	Sell	10,099,312 -1,622,327	-14%	-$153M	0.25%	59
2020 Q2	$1.15B	Sell	11,721,639 -2,352,596	-17%	-$207M	0.35%	38
2020 Q1	$1.07B	Buy	14,074,235 +1,682,474	+14%	+$143M	0.38%	39
2019 Q4	$1.1B	Sell	12,391,761 -357,093	-3%	-$29.6M	0.28%	61
2019 Q3	$965M	Buy	12,748,854 +2,124,794	+20%	+$146M	0.28%	57
2019 Q2	$773M	Sell	10,624,060 -318,664	-3%	-$25M	0.22%	74
2019 Q1	$882M	Sell	10,942,724 -1,594,114	-13%	-$130M	0.27%	61
2018 Q4	$1.16B	Sell	12,536,838 -744,850	-6%	-$65.5M	0.37%	35
2018 Q3	$1.26B	Buy	13,281,688 +671,132	+5%	+$63.6M	0.32%	39
2018 Q2	$1.17B	Sell	12,610,556 -591,734	-4%	-$57.8M	0.32%	41
2018 Q1	$1.25B	Buy	13,202,290 +52,460	+0.4%	+$5.76M	0.32%	37
2017 Q4	$1.27B	Buy	13,149,830 +3,329,292	+34%	+$314M	0.3%	42
2017 Q3	$873M	Buy	9,820,538 +145,552	+2%	+$11.1M	0.21%	65
2017 Q2	$702M	Buy	9,674,986 +1,455,125	+18%	+$97.8M	0.18%	83
2017 Q1	$536M	Buy	8,219,861 +516,801	+7%	+$32.5M	0.15%	113
2016 Q4	$482M	Buy	7,703,060 +876,569	+13%	+$53.5M	0.14%	125
2016 Q3	$431M	Buy	6,826,491 +594,674	+10%	+$38.5M	0.13%	130
2016 Q2	$386M	Buy	6,231,817 +246,811	+4%	+$15M	0.13%	132
2016 Q1	$342M	Sell	5,985,006 -978,064	-14%	-$54.5M	0.11%	170
2015 Q4	$412M	Buy	6,963,070 +1,071,006	+18%	+$61.7M	0.13%	149
2015 Q3	$321M	Sell	5,892,064 -812,905	-12%	-$52.9M	0.11%	175
2015 Q2	$451M	Sell	6,704,969 -1,897,429	-22%	-$124M	0.14%	134
2015 Q1	$504M	Sell	8,602,398 -299,039	-3%	-$18.1M	0.16%	113
2014 Q4	$583M	Sell	8,901,437 -1,234,931	-12%	-$77.9M	0.18%	89
2014 Q3	$585M	Buy	10,136,368 +2,376,782	+31%	+$132M	0.19%	85
2014 Q2	$438M	Buy	7,759,586 +453,120	+6%	+$23.8M	0.14%	135
2014 Q1	$376M	Sell	7,306,466 -1,109,340	-13%	-$56.1M	0.12%	156
2013 Q4	$444M	Buy	8,415,806 +1,496,836	+22%	+$73.6M	0.15%	128
2013 Q3	$309M	Sell	6,918,970 -77,132	-1%	-$3.42M	0.11%	172
2013 Q2	$289M	Buy	+6,996,102	New	+$306M	0.11%	170

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs's ABBV Position: Q1 2026 in Review

Goldman Sachs increased its AbbVie (ABBV) stake by 17% in Q1 2026, buying an estimated $477M and bringing the position to 15,145,279 shares worth $3.29B. The position accounts for 0.38% of the portfolio, ranked #28.

Goldman Sachs first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Goldman Sachs held 15,145,279 shares of AbbVie worth $3.29B as of Q1 2026.
Goldman Sachs bought 2,149,654 AbbVie shares in Q1 2026, an estimated $477M.
AbbVie made up 0.38% of Goldman Sachs's portfolio in Q1 2026, its #28 holding.
Goldman Sachs first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.